View in EDS HTML Full Text PDF Full Text

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.

Saved in:
Bibliographic Details
Title: A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.
Authors: Heumann, Thatcher R.1 (AUTHOR), Baretti, Marina1 (AUTHOR), Sugar, Elizabeth A.1,2 (AUTHOR), Durham, Jennifer N.1 (AUTHOR), Linden, Sheila1 (AUTHOR), Lopez-Vidal, Tamara Y.1 (AUTHOR), Leatherman, James1 (AUTHOR), Cope, Leslie1 (AUTHOR), Sharma, Anup1,3 (AUTHOR), Weekes, Colin D.4 (AUTHOR), O'Dwyer, Peter J.5 (AUTHOR), Reiss, Kim A.5 (AUTHOR), Monga, Dulabh K.6 (AUTHOR), Ahuja, Nita1,3 (AUTHOR), Azad, Nilofer S.1 (AUTHOR) Nazad2@jhmi.edu
Source: Clinical Epigenetics. 12/3/2022, Vol. 14 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:18687075
DOI:10.1186/s13148-022-01367-8